Mary Lou Chatterton
Senior Research Fellow and Co-Program Lead for Mental Health
Data updated
Research Footprint
Mary Lou Chatterton appears in 5 tracked papers (2023–2026), most studied alongside Ketamine and Esketamine, across Depressive Disorders, Treatment-Resistant Depression (TRD) and Suicidality.
Most-cited paper: Efficacy and safety of a 4-week course of repeated subcutaneous ketamine injections for treatment-resistant depression (KADS study): randomised double-blind active-controlled trial (64 citations).
Frequent co-authors: Anthony Rodgers, Colleen Loo and Paul Glue.
Background & Research
Dr Mary Lou Chatterton is a Senior Research Fellow and Co-Program Lead for Mental Health in the Monash University Health Economics Group. She holds a doctorate in clinical pharmacy and completed pharmacoeconomic research training, with a research focus on economic evaluations of medications, psychological interventions, and novel delivery systems for mental health conditions including depression and anxiety. Her Monash profile and publication record show her as a recurring author on the KADS ketamine trial and related economic/accessibility papers.
Key Impact
She is a health economist whose work has helped evaluate the value, access, and affordability of novel mental health treatments, including repeated subcutaneous ketamine for treatment-resistant depression.
Collaboration Network
5 collaborators· click a node to visit their profile
Full network →Collaboration Network
See Mary Lou Chatterton's full collaboration network, shared papers, and research connections.
Compounds
Topics
Top Collaborators
Top Collaborators
Unlock clinical summaries, full texts, and related trial mapping.
Affiliations
Institutions, companies, and organisations Mary Lou Chatterton is associated with.